Anti-LG3 Antibodies Aggravate Renal Ischemia–Reperfusion Injury and Long-Term Renal Allograft Dysfunction

American Journal of Transplantation

Volumn 16, Issue 12, 2016, Pages 3416-3429

  Yang, B ^a,b,c   Dieude M ^a,b,c   Hamelin, K ^a,b,c   Henault Rondeau M ^a,b,c   Patey, N ^a,b,c,d   Turgeon, J ^a,b,c   Lan, S ^a,b,c   Pomerleau, L ^a   Quesnel, M ^a   Peng, J ^a   Tremblay, J ^a   Shi, Y ^a,c   Chan, J S ^a,c   Hebert M J ^a,b,c   Cardinal, H ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Canadian National Transplant Research Program   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

autoimmunity; basic (laboratory) research science; clinical research practice; complement biology; delayed graft function (DGF); immunobiology; ischemia reperfusion injury (IRI); kidney (allograft) function dysfunction; kidney transplantation nephrology

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANTIBODY; LG3 ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; PERLECAN; PROTEOHEPARAN SULFATE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; FEMALE; HUMAN; IMMUNOMODULATION; KIDNEY ALLOGRAFT; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REPERFUSION INJURY; ANIMAL; BLOOD; C57BL MOUSE; CHRONIC KIDNEY FAILURE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ANIMALS; AUTOANTIBODIES; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PROGNOSIS; REPERFUSION INJURY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84978252767     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13866     Document Type: Article

References (49)

1. Cavaille-Coll M, Bala S, Velidedeoglu E, et al. Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation. Am J Transplant 2013; 13: 1134–1148.
2. Irish WD, McCollum DA, Tesi RJ, et al. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003; 14: 2967–2974.
3. Lechevallier E, Dussol B, Luccioni A, et al. Posttransplantation acute tubular necrosis: Risk factors and implications for graft survival. Am J Kidney Dis 1998; 32: 984–991.
4. Yarlagadda SG, Coca SG, Garg AX, et al. Marked variation in the definition and diagnosis of delayed graft function: A systematic review. Nephrol Dial Transplant 2008; 23: 2995–3003.
5. Wu WK, Famure O, Li Y, Kim SJ. Delayed graft function and the risk of acute rejection in the modern era of kidney transplantation. Kidney Int 2015; 88: 851–858.
6. Legendre C, Canaud G, Martinez F. Factors influencing long-term outcome after kidney transplantation. Transpl Int 2014; 27: 19–27.
7. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039–1047.
8. Boom H, Mallat MJ, de Fijter JW, de Fijter J, Zwinderman AH, Paul LC. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859–862.
9. Lapointe I, Lachance JG, Noel R, et al. Impact of donor age on long-term outcomes after delayed graft function: 10-year follow-up. Transpl Int 2013; 26: 162–169.
10. Verma SK, Molitoris BA. Renal endothelial injury and microvascular dysfunction in acute kidney injury. Semin Nephrol 2015; 35: 96–107.
11. Basile DP. The endothelial cell in ischemic acute kidney injury: Implications for acute and chronic function. Kidney Int 2007; 72: 151–156.
12. Bharat A, Saini D, Steward N, et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 2010; 90: 1094–1101.
13. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558–569.
14. Gao B, Moore C, Porcheray F, et al. Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. Am J Transplant 2014; 14: 1581–1591.
15. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886–892.
16. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, Rose ML. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007; 170: 1415–1427.
17. Cardinal H, Dieude M, Brassard N, et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant 2013; 13: 861–874.
18. Zhang M, Alicot EM, Carroll MC. Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model. Mol Immunol 2008; 45: 4036–4039.
19. Zhang M, Carroll MC. Natural IgM-mediated innate autoimmunity: A new target for early intervention of ischemia-reperfusion injury. Expert Opin Biol Ther 2007; 7: 1575–1582.
20. Zhang M, Austen WG Jr, Chiu I, et al. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2004; 101: 3886–3891.
21. Lukitsch I, Kehr J, Chaykovska L, et al. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 2012; 94: 8–13.
22. Shaffi K, Uhlig K, Perrone RD, et al. Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis 2014; 63: 1007–1018.
23. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272–283.
24. Wei Q, Dong Z. Mouse model of ischemic acute kidney injury: Technical notes and tricks. Am J Physiol Renal Physiol 2012; 303: F1487–F1494.
25. Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115: 2894–2903.
26. McCullough JW, Renner B, Thurman JM. The role of the complement system in acute kidney injury. Semin Nephrol 2013; 33: 543–556.
27. Ponticelli C. Ischaemia-reperfusion injury: A major protagonist in kidney transplantation. Nephrol Dial Transplant 2014; 29: 1134–1140.
28. Irish WD, Ilsley JN, Schnitzler MA, Feng S, Brennan DC. A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant 2010; 10: 2279–2286.
29. Thurman JM. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006; 116: 357–368.
30. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 2011; 7: 189–200.
31. Molitoris BA. Therapeutic translation in acute kidney injury: The epithelial/endothelial axis. J Clin Investig 2014; 124: 2355–2363.
32. Basile DP, Friedrich JL, Spahic J, et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol 2011; 300: F721–F733.
33. Horbelt M, Lee SY, Mang HE, et al. Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol 2007; 293: F688–F695.
34. Basile DP, Yoder MC. Renal endothelial dysfunction in acute kidney ischemia reperfusion injury. Cardiovasc Hematol Disord Drug Targets 2014; 14: 3–14.
35. Soulez M, Pilon EA, Dieude M, et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ Res 2012; 110: 94–104.
36. Dieude M, Bell C, Turgeon J, et al. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med 2015; 7: 318ra200.
37. Haase M, Bellomo R, Albert C, et al. The identification of three novel biomarkers of major adverse kidney events. Biomark Med 2014; 8: 1207–1217.
38. Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, Molitoris BA. Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol 2003; 285: F191–F198.
39. Giral M, Foucher Y, Dufay A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013; 13: 2567–2576.
40. Angaswamy N, Klein C, Tiriveedhi V, et al. Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy. Am J Transplant 2014; 14: 685–693.
41. Joosten SA, Sijpkens YW, van Ham V, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5: 383–393.
42. Besarani D, Cerundolo L, Smith JD, et al. Role of anti-vimentin antibodies in renal transplantation. Transplantation 2014; 98: 72–78.
43. Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530–536.
44. Becker MO, Kill A, Kutsche M, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 2014; 190: 808–817.
45. Kill A, Tabeling C, Undeutsch R, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014; 16: R29.
46. Xiong J, Liang Y, Yang H, Zhu F, Wang Y. The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis. Int J Clin Pract 2013; 67: 1066–1067.
47. Hirt-Minkowski P, Roth M, Honger G, Amico P, Hopfer H, Schaub S. Soluble CD30 correlates with clinical but not subclinical renal allograft rejection. Transpl Int 2013; 26: 75–83.
48. Summers DM, Johnson RJ, Allen J, et al. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: A cohort study. Lancet 2010; 376: 1303–1311.
49. Singh RP, Farney AC, Rogers J, et al. Kidney transplantation from donation after cardiac death donors: Lack of impact of delayed graft function on post-transplant outcomes. Clin Transplant 2011; 25: 255–264.